(UEF5) UBS MSCI Emerging Markets - Ratings and Ratios
Emerging Markets, Equity, Sustainable Investing, ESG, ETF, UCITS, Global
Description: UEF5 UBS MSCI Emerging Markets
The UBS MSCI Emerging Markets Socially Responsible UCITS A-dis (XETRA:UEF5) is an exchange-traded fund (ETF) that tracks the Morningstar Emerging Markets TME NR USD Index, providing investors with exposure to a diversified portfolio of emerging markets equities that adhere to socially responsible investing (SRI) principles.
As a Global Emerging Markets Equity ETF, UEF5 offers a broad-based investment opportunity, allowing investors to tap into the growth potential of emerging markets while considering environmental, social, and governance (ESG) factors. The fund is listed on the XETRA exchange and originates from Germany.
Analyzing the funds recent performance, we observe that the last price is 13.35, indicating a positive trend as it is above both the 20-day simple moving average (SMA20) of 13.06 and the 50-day simple moving average (SMA50) of 12.47. The 200-day simple moving average (SMA200) is 12.79, further supporting the notion of an upward trend. The average true range (ATR) is 0.15, representing a 1.15% daily price fluctuation, suggesting relatively moderate volatility.
With assets under management (AUM) of 2045.60M EUR, the fund demonstrates a significant presence in the market, indicating investor confidence and liquidity. The 52-week high and low prices are 13.61 and 10.84, respectively, showing the funds price resilience and growth potential over the past year.
Forecasting the funds future performance, we can infer from the technical data that the upward trend may continue, given the current prices position above key moving averages. Fundamentally, the substantial AUM and the funds adherence to SRI principles, which are increasingly popular among investors, support a positive outlook. Assuming the emerging markets continue to grow and the ESG considerations remain a priority, UEF5 is likely to remain an attractive investment option. Therefore, a potential target price could be in the range of 14.00 to 14.50, representing a 5% to 8% increase from the current price, contingent upon favorable market conditions and continued investor interest in SRI-focused investments.
Additional Sources for UEF5 ETF
UEF5 ETF Overview
Market Cap in USD | 2,380m |
Category | Global Emerging Markets Equity |
TER | 0.20% |
IPO / Inception | 2014-09-04 |
UEF5 ETF Ratings
Growth Rating | 27.5 |
Fundamental | - |
Dividend Rating | 45.4 |
Rel. Strength | -12.3 |
Analysts | - |
Fair Price Momentum | 12.67 EUR |
Fair Price DCF | - |
UEF5 Dividends
Dividend Yield 12m | 2.37% |
Yield on Cost 5y | 3.20% |
Annual Growth 5y | -1.60% |
Payout Consistency | 93.5% |
Payout Ratio | % |
UEF5 Growth Ratios
Growth Correlation 3m | 94.4% |
Growth Correlation 12m | 46.5% |
Growth Correlation 5y | 13% |
CAGR 5y | 6.80% |
CAGR/Max DD 5y | 0.27 |
Sharpe Ratio 12m | 0.88 |
Alpha | 5.02 |
Beta | 0.718 |
Volatility | 14.51% |
Current Volume | 38.8k |
Average Volume 20d | 37.8k |
Stop Loss | 13.4 (-3.3%) |
As of July 18, 2025, the stock is trading at EUR 13.86 with a total of 38,791 shares traded.
Over the past week, the price has changed by +0.95%, over one month by +4.20%, over three months by +19.32% and over the past year by +15.23%.
Neither. Based on ValueRay´s Analyses, UBS MSCI Emerging Markets is currently (July 2025) neither a good nor a bad stock to buy. It has a ValueRay Growth Rating of 27.51 and therefor a technical neutral rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of UEF5 is around 12.67 EUR . This means that UEF5 is currently overvalued and has a potential downside of -8.59%.
UBS MSCI Emerging Markets has no consensus analysts rating.
According to our own proprietary Forecast Model, UEF5 UBS MSCI Emerging Markets will be worth about 14.5 in July 2026. The stock is currently trading at 13.86. This means that the stock has a potential upside of +4.4%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 14.5 | 4.4% |